CAPUTO, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.377
AS - Asia 1.946
EU - Europa 1.438
AF - Africa 582
SA - Sud America 504
OC - Oceania 63
Continente sconosciuto - Info sul continente non disponibili 35
Totale 11.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.052
SG - Singapore 616
HK - Hong Kong 358
CN - Cina 347
BR - Brasile 319
FI - Finlandia 172
DE - Germania 145
UA - Ucraina 118
SE - Svezia 97
FR - Francia 93
IT - Italia 89
VN - Vietnam 81
PL - Polonia 80
GB - Regno Unito 60
RU - Federazione Russa 59
AT - Austria 31
AR - Argentina 29
IE - Irlanda 29
IQ - Iraq 29
UZ - Uzbekistan 28
PT - Portogallo 27
NL - Olanda 25
TR - Turchia 25
AL - Albania 24
EC - Ecuador 24
HR - Croazia 24
ME - Montenegro 24
ES - Italia 23
IN - India 23
YT - Mayotte 23
GF - Guiana Francese 22
GT - Guatemala 22
ZM - Zambia 22
TT - Trinidad e Tobago 21
AO - Angola 20
BS - Bahamas 20
CH - Svizzera 20
IR - Iran 20
NP - Nepal 20
PE - Perù 20
PK - Pakistan 20
SI - Slovenia 20
XK - ???statistics.table.value.countryCode.XK??? 20
GP - Guadalupe 19
JM - Giamaica 19
MA - Marocco 19
MX - Messico 19
VE - Venezuela 19
ZA - Sudafrica 19
BA - Bosnia-Erzegovina 18
CA - Canada 18
CO - Colombia 18
CZ - Repubblica Ceca 18
GR - Grecia 18
HN - Honduras 18
HU - Ungheria 18
JP - Giappone 18
RS - Serbia 18
AE - Emirati Arabi Uniti 17
CI - Costa d'Avorio 17
CV - Capo Verde 17
EG - Egitto 17
JO - Giordania 17
LU - Lussemburgo 17
LY - Libia 17
NI - Nicaragua 17
RO - Romania 17
AM - Armenia 16
AZ - Azerbaigian 16
BB - Barbados 16
CG - Congo 16
DJ - Gibuti 16
GA - Gabon 16
KR - Corea 16
MG - Madagascar 16
MN - Mongolia 16
MZ - Mozambico 16
NE - Niger 16
PY - Paraguay 16
RE - Reunion 16
SN - Senegal 16
TN - Tunisia 16
TW - Taiwan 16
BE - Belgio 15
CR - Costa Rica 15
CW - ???statistics.table.value.countryCode.CW??? 15
CY - Cipro 15
DO - Repubblica Dominicana 15
ET - Etiopia 15
GE - Georgia 15
ID - Indonesia 15
IS - Islanda 15
MD - Moldavia 15
MK - Macedonia 15
MY - Malesia 15
NG - Nigeria 15
PA - Panama 15
PH - Filippine 15
PS - Palestinian Territory 15
SA - Arabia Saudita 15
Totale 11.281
Salva come PNG Salva come JPEG
Città #
Fairfield 884
Woodbridge 813
Houston 756
Ann Arbor 675
Jacksonville 490
Ashburn 482
Santa Clara 430
Hong Kong 342
Singapore 341
Wilmington 334
Seattle 331
Cambridge 313
Chandler 273
Princeton 196
Boardman 154
San Diego 112
Beijing 72
Bytom 62
Medford 53
Nanjing 53
Helsinki 50
Des Moines 33
Roxbury 26
São Paulo 26
Tashkent 26
Hebei 25
Dublin 24
Guangzhou 23
Los Angeles 23
Ho Chi Minh City 22
Lusaka 21
Podgorica 21
Munich 20
Luanda 19
Shenyang 19
Nassau 18
New York 18
Amman 17
Changsha 17
Norwalk 17
Antananarivo 16
Cayenne 16
Dakar 16
Libreville 16
Lima 16
Managua 16
Ulan Bator 16
Vienna 16
Hanoi 15
Jiaxing 15
Nanchang 15
Panama City 15
Pristina 15
Yerevan 15
Abidjan 14
Baku 14
Mamoudzou 14
Praia 14
Bridgetown 13
Chicago 13
Dar es Salaam 13
Djibouti 13
Maputo 13
Niamey 13
Nuremberg 13
Padova 13
Vientiane 13
Accra 12
Bishkek 12
Conakry 12
Dong Ket 12
Harare 12
Havana 12
Kampala 12
Kingston 12
Montevideo 12
Nairobi 12
Reykjavik 12
Riga 12
Rio de Janeiro 12
San José 12
Tirana 12
Willemstad 12
Abu Dhabi 11
Baghdad 11
Dushanbe 11
Guatemala City 11
Kigali 11
Les Abymes 11
Nouakchott 11
Noumea 11
Quito 11
Roseau 11
Zagreb 11
Addis Ababa 10
Belgrade 10
Brazzaville 10
Castries 10
Chaguanas 10
Guayaquil 10
Totale 8.395
Salva come PNG Salva come JPEG
Nome #
Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. 181
Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. 181
Biocompatible Anionic Polymeric Microspheres as Priming Delivery System for Effetive HIV/AIDS Tat-Based Vaccines 172
Control of SHIV-89.6p infection of cynomolgus monkeys by the HIV-1 tat protein vaccine 164
Hpv-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy 159
Characterization of immune responses elicited in mice by intranasal co immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. 156
Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. 155
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. 154
The Sp1 transcription factor does not directly interact with the HIV-1 Tat protein 151
Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. 149
Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication 147
Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL 147
Adenovirus type 12 early region 1A proteins repress class I HLA expression in transformed human cells. 147
HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity 146
Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes. 146
Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules. 146
Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application 141
Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) 141
Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. 139
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells 137
Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. 137
Cooperation in oncogenesis between BK virus early region gene and the activated human c-Harvey ras oncogene. 136
Co-operation in cell transformation between BK virus and the human c-Harvey-ras oncogene. 136
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles. 135
Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1 infected patients 134
Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156 and PNU 153429, on HIV type 1 Tat protein 132
Interaction of Sp1 transcription factor with HIV-1 Tatprotein: looking for cellular partners. 132
Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes 132
Pentosan polysulfate as inhibitor of extracellular HIV-1 Tat 130
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines 130
Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection 128
The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells. 128
HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors. 127
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). 125
Oncogenity of BK virus for immunosuppressed hamsters. 124
Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application 124
BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli. 123
Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders. 123
An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge 123
Transcription pattern of the K3 open reading frame of HHV8 in primary effusion lymphoma and Kaposi's sarcoma 122
Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens. 122
Recent advances in the development of HIV-1 Tat-based vaccines 121
Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection. 121
Transformation of human embryonic fibroblasts by BK virus, BK virus DNA and a subgenomic BK virus DNA fragment. 119
Problems and emerging approaches in HIV/AIDS vaccine development. 119
HIV-1 Tat-Based Vaccines: An Overview and Perspectives in the Field of HIV/AIDS Vaccine Development. 118
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. 118
HIV-1 Tat-based vaccines: from basic science to clinical trials 117
The systemic administration of a low dose of 20MePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model 117
Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene 116
New BK virus episomal vector for complementary DNA expression in human cells. 116
Expression of hepatitis B surface antigen in human cells by a recombinant BK virus DNA vector. 116
Prevalence of liver tumours in HIV-1 tat-transgenic mice treated with urethane 115
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccines against AIDS. 114
Episomal DNA of a BK virus variant in a human insulinoma. 114
DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune response and strongly enhance cellular responses of HIV-1 tat DNA vaccination. 114
Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. 112
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine 112
Reexamination of the coding potential of the HTLV-1 pX region. 110
Inhibition of HIV-1 Tat activity correlates with down-regulation of bcl-2 and results in reduction of angiogenesis and oncogenicity. 110
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi’s sarcoma via induction of basic fibroblast growth factor and the αvβ3 integrin 107
Transformation of hamster kidney cells by fragments of BK virus DNA 105
Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. 104
High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B. 104
Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. 103
Reciprocal in vitro interactions between human herpesvirus-6 and HIV-1 Tat. 103
The presence of anti-Tat antibodies is predictive of long-term non-progression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters 103
Formation of oligomeric free BK virus DNA is required for tandem integration of viral genomes into cellular DNA. 102
DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune response against wild-type Tat. 102
Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region 101
Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. 101
SHIV89.6P pathogencity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine 100
The HIV-1 regulatory genes tat and rev as targets for gene therapy. 100
MULTIPLE FUNCTIONS OF IMMUNODEFICIENCY VIRUS TYPE 1 TAT PROTEIN IN THE PATHOGENESIS OF AIDS. 99
Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein. 99
HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection 99
Morphological, histochemical, immunohistochemical and ultrastuctural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice 97
Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Krüppel-associated box repressor domain targeted to the transactivating response element. 97
Protein friendly core-shell microspheres by dispersion polymerization as promising delivery systems for proteins 97
Transiently transfected and stably integrated HIV-1 provirus responds differentially to the silencing activity of the Kruppel-associated box (KRAB) 94
Functional polymeric nano/microparticles for protein and DNA vaccine delivery. 94
The increase in intra-macrophage thiols induced by new pro-GSH molecules directs the Th1 skewing in ovalbumin immunized mice. 92
Nanoparticles for delivery of a pharmacologically active agent (United Kingdom Patent application) 90
Induction of malignant subcutaneous sarcomas in hamsters by a recombinant DNA containing BK virus early region and the activated human c-Harvey-ras oncogene. 90
Complex associates of plasmid DNA and novel class of block copolymers with poly(ethylene glycol)and cationic segments as new vectors for gene delivery 90
Sequence conservation and antibody cross-recognition of the clade B HIV-1 Tat protein vaccine candidate in HIV-1-infected Italian, Ugandan and Soth African individuals 89
The tat gene and protein of the human immunodeficiency virus type 1. 88
Long term protection against SHIV89.6P replication in Tat protein or tat DNA vaccinated cynomolgus monkeys upon tetanus toxoid boost and correlation with Tat immune response 87
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. 87
Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-beta1 84
Viral Vaccines 84
Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers greatly enhances the CTL response against Tat 84
The exogenous transactivation activity of HIV-1 tat. 83
Recombinant Herpes Simplex Virus and uses therefor (United Kingdom Patent application) 80
Development of HIV/AIDS vaccine based on Tat: preclinical and clinical studies. 80
Effect of tat transdominant negative mutants on HIV-1 replication in Jurkat T cell lines. 78
Factors affecting amplification of BK virus episomal vectors in human cells. Brief report. 77
Antiangiogenic, antitumoral and antimetastatic effects of two dystamicyn derivatives with anti-HIV-1 tat activity in a Kaposi's Sarcoma-like murine model 77
Micellar-type complexes of taylor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. 72
Vaccines (United Kingdom Patent application) 69
Totale 11.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.996
article - articoli 35.959
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 1.049
selected - selezionate 0
volume - volumi 660
Totale 75.664
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021691 0 0 0 81 42 59 31 90 132 87 111 58
2021/20221.287 32 206 204 103 23 36 74 154 38 16 174 227
2022/2023763 204 17 4 59 150 115 2 76 83 4 39 10
2023/2024359 13 49 47 40 12 41 9 22 15 7 50 54
2024/20252.117 2 74 97 74 532 44 69 131 215 69 373 437
2025/20262.654 184 641 1.152 677 0 0 0 0 0 0 0 0
Totale 11.967